Tag Archives: healthcare

Managed Entry Trumps Risk Sharing

Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Alzheimer’s Disease “Robs You of Everything”

Alzheimer’s Disease “Robs You of Everything”

George Hendrick and his wife, Mary Lee, experienced the typical highs and lows of parenthood as they raised nine children in New Lenox, a south suburb of Chicago. After the couple’s nest was nearly empty, in what was supposed to be their golden years, George was told he had memory and thinking problems, and later, Alzheimer’s disease. George’s long tenure as a Will County police officer was cut short. He could no longer carry a gun, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Biomedical R&D in the 21st Century

Dale Edgar

Reflecting back upon my career,  I recognize the importance academic-industry research partnerships played in shaping my philosophy as a scientist and research leader.  Something deeply fulfilling happens when basic and applied scientists ally, and our individual passion to make a difference in the life of a patient merges into a community effort. We are moving ever closer to solving some of the toughest biomedical challenges of our time.  But this is also an era of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

#BIO 2013: Open Innovation and Biopharmaceutical R&D

Menelas Pangalos

In these changing times, the concept of Open Innovation is one that we at AstraZeneca have fully embraced. By sharing new ideas and enabling scientific innovation to cross boundaries between companies, academia, government and non-profit organizations, we can accelerate new ideas into innovative medicines. An Open Innovation discussion at BIO I will discuss the importance that AstraZeneca places on Open Innovation today at this year’s BIO International Convention. An interactive session will include a panel discussion and presentations Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Q & A with Eli Lilly’s Eric Siemers

Q+A with Eli Lillys Eric Siemers

In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase 3, double-blind, placebo-controlled studies of the anti-amyloid antibody solanezumab, in patients with mild-to-moderate Alzheimer’s disease. Although cognitive decline was slowed in patients with early stage disease in one trial, and there were also positive signs from the other trial, those findings were not statistically significant. But a secondary analysis conducted independently by a panel of academic researchers pooled data from Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,